Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.

Saved in:
Bibliographic Details
Title: Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Authors: Grosicki S; Medical University of Silesia, Katowice, Poland. Electronic address: sgrosicki@wp.pl., Simonova M; Institute of Blood Pathology and Transfusion Medicine, National Academy of Medical Sciences of Ukraine, Lviv, Ukraine., Spicka I; Charles University and General Hospital, Prague, Czech Republic., Pour L; Clinic of Internal Medicine-Hematology and Oncology, University Hospital Brno, Brno, Czech Republic., Kriachok I; National Cancer Institute Ukraine, Kiev, Ukraine., Gavriatopoulou M; Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Pylypenko H; Department of Hematology, Cherkassy Regional Oncological Center, Cherkassy, Ukraine., Auner HW; Imperial College London, London, UK., Leleu X; Department of Hematology, CHU la Miletrie and Inserm CIC 1402, Poitiers, France., Doronin V; City Clinical Hospital No. 40, Moscow, Russia., Usenko G; City Clinical Hospital 4 of Dnipro City Council, City Hematology Center, Dnipro, Ukraine., Bahlis NJ; Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada., Hajek R; Department of Hemato-oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Benjamin R; Kings College NHS Foundation Trust, Kings College London, London, UK., Dolai TK; Nil Ratan Sircar Medical College and Hospital, Kolkata, India., Sinha DK; State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Patna, India., Venner CP; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada., Garg M; University Hospitals of Leicester NHS Trust, Leicester, UK., Gironella M; Vall d'Hebron University Hospital, Barcelona, Spain., Jurczyszyn A; Department of Hematology, Jagiellonian University Medical College, Kraków, Poland., Robak P; Department of Hematology, Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland., Galli M; Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy., Wallington-Beddoe C; Flinders Medical Centre and Flinders University, Adelaide, SA, Australia., Radinoff A; University Hospital 'St Ivan Rilski' EAD, Sofia, Bulgaria., Salogub G; Chemotherapy of Oncology Diseases-Bone Marrow Transplantation Department 1, Almazov National Medical Research Centre, Ministry of Health of Russia, St Petersburg, Russia., Stevens DA; Norton Cancer Institute, St Matthews Campus, Louisville, KY, USA., Basu S; New Cross Hospital, Royal Wolverhampton NHS Trust and University of Wolverhampton, Wolverhampton, UK., Liberati AM; Oncohematology Hospital S Maria Terni, University of Perugia, Terni, Italy., Quach H; University of Melbourne, St Vincent's Hospital, Melbourne, VIC, Australia., Goranova-Marinova VS; University Hospital 'Sv Georgi' EAD, Clinic of Clinical Hematology, Medical University of Plovdiv, Plovdiv, Bulgaria., Bila J; Clinic for Hematology, Clinical Centre of Serbia, Belgrade, Serbia., Katodritou E; Hematology Department, Theagenion Cancer Hospital, Thessaloniki, Greece., Oliynyk H; Department of Hematology, Vinnytsia M I Pyrohov Regional Clinical Hospital, Vinnytsia, Ukraine., Korenkova S; Bone Marrow Transplantation Department, Kyiv Bone Marrow Transplantation Center, Kyiv, Ukraine., Kumar J; Tata Medical Center, Kolkata, India., Jagannath S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Moreau P; University Hospital, Hotel-Dieu, Nantes, France., Levy M; Baylor University Medical Center, Dallas, TX, USA., White D; Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS, Canada., Gatt ME; Hadassah Hebrew University Medical Center, Jerusalem, Israel., Facon T; CHU Lille Service des Maladies du Sang F-59000, Lille, France., Mateos MV; Hospital Universitario de Salamanca, Salamanca, Spain., Cavo M; Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy., Reece D; University Health Network-Princess Margaret Cancer Centre, Toronto, ON, Canada., Anderson LD Jr; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA., Saint-Martin JR; Karyopharm Therapeutics, Newton, MA, USA., Jeha J; Karyopharm Therapeutics, Newton, MA, USA., Joshi AA; Karyopharm Therapeutics, Newton, MA, USA., Chai Y; Karyopharm Therapeutics, Newton, MA, USA., Li L; Karyopharm Therapeutics, Newton, MA, USA., Peddagali V; Karyopharm Therapeutics, Newton, MA, USA., Arazy M; Karyopharm Therapeutics, Newton, MA, USA., Shah J; Karyopharm Therapeutics, Newton, MA, USA., Shacham S; Karyopharm Therapeutics, Newton, MA, USA., Kauffman MG; Karyopharm Therapeutics, Newton, MA, USA., Dimopoulos MA; School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Richardson PG; Dana-Farber Cancer Institute, Boston, MA, USA., Delimpasi S; General Hospital Evangelismos, Athens, Greece.
Source: Lancet (London, England) [Lancet] 2020 Nov 14; Vol. 396 (10262), pp. 1563-1573.
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-547X
DOI:10.1016/S0140-6736(20)32292-3